UroGen Pharma Ltd. (URGN) ownership: insiders 1% · institutions 97% · index and ETF funds 0% (13F 2026-03-31). Insider activity, 90 days: Routine (2 sales, 0 open-market buys). SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| RTW Investments, LP | 4543895.00 | $81.70M | 9.3% | 2026-03-31 |
| BlackRock | 2845567.00 | $51.16M | 5.8% | 2026-03-31 |
| TD Asset Management | 2616714.00 | $47.05M | 5.4% | 2026-03-31 |
| Morgan Stanley | 2560038.00 | $46.03M | 5.3% | 2026-03-31 |
| Kynam Capital Management, LP | 2247393.00 | $40.41M | 4.6% | 2026-03-31 |
| Jefferies | 2199652.00 | $39.55M | 4.5% | 2026-03-31 |
| Paradigm Biocapital Advisors LP | 1703949.00 | $30.64M | 3.5% | 2026-03-31 |
| Acorn Capital Advisors, LLC | 1673420.00 | $30.09M | 3.4% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-22 |
Back to URGN overview · URGN earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.